Leucemia mielóide aguda em crianças e adolescentes em instituições Brasileiras: realidade e desafios

Authors

  • Ana Luiza de Melo Rodrigues Department of Pediatric Oncology and Bone Marrow Transplant, Erasto Gaertner Hospital, Curitiba – PR, Brazil https://orcid.org/0000-0002-2346-7194
  • Luana Lenzi Department of Clinical Analysis, Federal University of Paraná, Curitiba - PR, Brazil https://orcid.org/0000-0002-4829-1703
  • Lisa Lee-Jones Department of Life Sciences, Manchester Metropolitan University, Manchester, United Kingdom https://orcid.org/0000-0003-1255-3545
  • Alayde Vieira Wanderley Department of Pediatric Oncology, Hospital Oncológico Octávio Lobo, Belém – PA, Brazil
  • Ana Maria Marinho Da Silva Department of Pediatric Oncology, Aristides Maltez Hospital, Salvador – BA, Brazil
  • Cinthya Rocha De Carvalho Department of Pediatric Oncology, Institute of Integral Medicine Professor Fernando Figueira – IMIP, Recife – PE, Brazil
  • Juliana Teixeira Costa Department of Pediatric Oncology, Martagão Gesteira Hospital, Salvador – BA, Brazil
  • Cláudio Galvão De Castro Junior Department of Pediatric Oncology, Santo Antonio Children's Hospital, Porto Alegre – RS, Brazil
  • Maria Lucia De Martino Lee Brazilian Childhood Leukemia Treatment Group (GBTLI) - Coordinator
  • Mecneide Mendes Lins Department of Pediatric Oncology, Institute of Integral Medicine Professor Fernando Figueira – IMIP, Recife – PE, Brazil
  • Patrick Rezende Godinho Department of Pediatric Oncology, Fundação Pio XII - Amor da Amazônia Hospital, Porto Velho – RO, Brazil
  • Raul Correa Ribeiro Department of Oncology and Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis - TN, USA https://orcid.org/0000-0002-9956-5647

DOI:

https://doi.org/10.46765/2675-374X.2020v2n1p77-86

Keywords:

Pediatric AML. HSCT. Brazil

Abstract

Objective: To describe the outcome of acute myeloid leukemia (AML) among children treated in Brazilian institutions. Methods: A structured online questionnaire was sent to pediatric oncologists affiliated to the Brazilian Society of Pediatric Oncology. The physicians and institutions were unidentified. Results: One hundred and four pediatric oncologists in all Brazilian regions answered the questionnaire. The treatment-related mortality rate was reported to be higher than 30% by 29.8% of the participants. Difficulty in accessing the intensive care unit (ICU) was reported by 54.8%. About 85% had access to cytogenetics, 78% to molecular testing, 94% to the measurement of residual disease by flow cytometry. About 90% of participants reported access to HSCT, but 86% of them had difficulties in providing HSCT timely. About 95% of the respondents indicated the need to create a national treatment protocol, and 89.4% are willing to collaborate with a national study group. Conclusion: Our study demonstrated large gaps in the treatment of pediatric AML in Brazil. To improve outcome, a national protocol will have to consider the regional differences and adapt the management according to the local resources.

Downloads

Published

10/14/2020

How to Cite

de Melo Rodrigues, A. L., Lenzi, L., Lee-Jones, L., Vieira Wanderley, A., Marinho Da Silva, A. M., Rocha De Carvalho, C., … Correa Ribeiro, R. (2020). Leucemia mielóide aguda em crianças e adolescentes em instituições Brasileiras: realidade e desafios. JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, 1(3), 77–86. https://doi.org/10.46765/2675-374X.2020v2n1p77-86

Issue

Vol. 1 No. 3 (2020): Journal of Bone Marrow Transplantation and Cellular Therapy

Section

Original article

License

License and Copyright Policy

The Journal of Bone Marrow Transplantation and Cellular Therapy (JBMTCT) adopts an open access policy, ensuring that all published articles are freely available to the public without restrictions.

  1. License

    • All articles published in JBMTCT are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
    • This license permits anyone to:
      • Share: Copy and redistribute the material in any medium or format.
      • Adapt: Remix, transform, and build upon the material for any purpose, even commercially.
    • The only requirement is that appropriate credit is given to the original authors and source, a link to the license is provided, and any changes made are indicated.

    More information about the license can be found here: Creative Commons Attribution 4.0 International License.

  2. Authors’ Rights

    • Authors retain the copyright to their work.
    • Authors grant JBMTCT the right to publish the work and make it openly accessible online.
    • Authors are free to:
      • Distribute the published version of their article (e.g., post it on personal websites or institutional repositories).
      • Use the article in future works, presentations, or derivative publications, as long as the original publication in JBMTCT is properly acknowledged.

  3. No Embargo

    • There is no embargo period; articles are made freely available immediately upon publication.

  4. Ethical Use

    • Users of JBMTCT articles must ensure proper citation of the authors and the journal.
    • Articles must not be used in ways that violate ethical or legal standards.

  5. Disclaimer

    • While JBMTCT aims to ensure the accuracy and reliability of published content, the journal and its editors are not responsible for the consequences of its use.

For any questions regarding our licensing terms, please contact us at: journalbmtct@sbtmo.org.br 

JBMTCT is committed to the principles of open access to advance knowledge and scientific collaboration.

 

Similar Articles

<< < 6 7 8 9 10 11 

You may also start an advanced similarity search for this article.